DDInter1838 DDInter1676
Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Tositumomab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Tositumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Tositumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Tositumomab {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Tositumomab {u} may lead to a major life threatening interaction when taken with {v} Bivalirudin
Tositumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Ketorolac
Tositumomab may cause a minor interaction that can limit clinical effects when taken with Capsicum
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Tositumomab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Tositumomab may lead to a major life threatening interaction when taken with Bivalirudin
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Tositumomab may lead to a major life threatening interaction when taken with Ketorolac